AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Genelux Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

The Form 4 filing reports that Chemours Company (CC) director Courtney Mather was awarded 2,292 deferred stock units (DSUs) on 30 June 2025. Each DSU equals one share of common stock and will be settled in the first month after the director leaves the board. The award is recorded at a reference price of $11.45 per unit. After the grant, Mather directly owns 2,292 derivative securities; no sales or additional purchases of common stock were disclosed. Apart from this routine director compensation grant, the filing contains no other material transactions or changes in ownership.

Il modulo Form 4 riporta che la direttrice di Chemours Company (CC), Courtney Mather, ha ricevuto 2.292 unità di azioni differite (DSU) il 30 giugno 2025. Ogni DSU corrisponde a una azione ordinaria e verrà liquidato nel primo mese successivo all'uscita della direttrice dal consiglio. Il premio è stato registrato a un prezzo di riferimento di 11,45 $ per unità. Dopo l'assegnazione, Mather detiene direttamente 2.292 titoli derivati; non sono state comunicate vendite o ulteriori acquisti di azioni ordinarie. A parte questo compenso ordinario per il direttore, il documento non contiene altre transazioni rilevanti o variazioni nella proprietà.

El formulario Form 4 informa que la directora de Chemours Company (CC), Courtney Mather, recibió 2,292 unidades de acciones diferidas (DSU) el 30 de junio de 2025. Cada DSU equivale a una acción común y se liquidará en el primer mes después de que la directora deje la junta. La concesión se registró a un precio de referencia de $11.45 por unidad. Tras la concesión, Mather posee directamente 2,292 valores derivados; no se divulgaron ventas ni compras adicionales de acciones comunes. Aparte de esta compensación rutinaria para directores, el informe no contiene otras transacciones materiales ni cambios en la propiedad.

Form 4 ì œì¶œì„œì— ë”°ë¥´ë©� Chemours Company(CC) ì´ì‚¬ Courtney Matherê°€ 2025ë…� 6ì›� 30ì¼ì— 2,292ê°œì˜ ì´ì—° ì£¼ì‹ ë‹¨ìœ„(DSU)ë¥� 수여받았습니ë‹�. ê°� DSUëŠ� 보통ì£� í•� ì£¼ì— í•´ë‹¹í•˜ë©°, ì´ì‚¬ê°€ ì´ì‚¬íšŒì—ì„� 물러ë‚� í›� ì²� ë‹¬ì— ì •ì‚°ë©ë‹ˆë‹�. 수여ëŠ� 단위ë‹� $11.45ì� 기준 가격으ë¡� 기ë¡ë˜ì—ˆìŠµë‹ˆë‹�. 수여 í›� MatherëŠ� ì§ì ‘ 2,292ê°œì˜ íŒŒìƒ ì¦ê¶Œì� 보유하고 있으ë©�, 보통ì£� 매ë„ë‚� 추가 매수ëŠ� 공개ë˜ì§€ 않았습니ë‹�. ì� ì¼ìƒì ì¸ ì´ì‚¬ ë³´ìƒ ì™¸ì—ëŠ� ì œì¶œì„œì— ë‹¤ë¥¸ 중요í•� 거래ë‚� 소유ê¶� ë³€ë™ì´ 없습니다.

Le formulaire Form 4 indique que la directrice de Chemours Company (CC), Courtney Mather, a reçu 2 292 unités d'actions différées (DSU) le 30 juin 2025. Chaque DSU équivaut à une action ordinaire et sera réglée dans le premier mois suivant le départ de la directrice du conseil d'administration. L'attribution est enregistrée à un prix de référence de 11,45 $ par unité. Après l'attribution, Mather détient directement 2 292 titres dérivés ; aucune vente ni achat supplémentaire d'actions ordinaires n'a été divulgué. En dehors de cette attribution de rémunération habituelle pour les administrateurs, le dépôt ne contient aucune autre transaction importante ni changement de propriété.

Das Formular Form 4 berichtet, dass die Direktorin von Chemours Company (CC), Courtney Mather, am 30. Juni 2025 mit 2.292 aufgeschobenen Aktienanteilen (DSUs) ausgezeichnet wurde. Jede DSU entspricht einer Stammaktie und wird im ersten Monat nach dem Ausscheiden der Direktorin aus dem Vorstand abgewickelt. Die Zuteilung wurde zu einem Referenzpreis von 11,45 $ pro Einheit erfasst. Nach der Zuteilung besitzt Mather direkt 2.292 derivative Wertpapiere; Verkäufe oder zusätzliche Käufe von Stammaktien wurden nicht offengelegt. Abgesehen von dieser routinemäßigen Vergütung für Direktoren enthält die Meldung keine weiteren wesentlichen Transaktionen oder Eigentumsänderungen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR—Routine director equity grant; neutral impact, signals standard board alignment.

This Form 4 simply records a scheduled equity award: 2,292 DSUs granted to director Courtney Mather at a reference price of $11.45. DSUs settle after board service ends, so the grant aligns the director’s incentives with long-term shareholder value but does not represent an open-market purchase. No shares were sold, and the total position now matches the grant amount. Given the modest size and routine nature, the disclosure is not materially impactful for valuation or trading decisions.

Il modulo Form 4 riporta che la direttrice di Chemours Company (CC), Courtney Mather, ha ricevuto 2.292 unità di azioni differite (DSU) il 30 giugno 2025. Ogni DSU corrisponde a una azione ordinaria e verrà liquidato nel primo mese successivo all'uscita della direttrice dal consiglio. Il premio è stato registrato a un prezzo di riferimento di 11,45 $ per unità. Dopo l'assegnazione, Mather detiene direttamente 2.292 titoli derivati; non sono state comunicate vendite o ulteriori acquisti di azioni ordinarie. A parte questo compenso ordinario per il direttore, il documento non contiene altre transazioni rilevanti o variazioni nella proprietà.

El formulario Form 4 informa que la directora de Chemours Company (CC), Courtney Mather, recibió 2,292 unidades de acciones diferidas (DSU) el 30 de junio de 2025. Cada DSU equivale a una acción común y se liquidará en el primer mes después de que la directora deje la junta. La concesión se registró a un precio de referencia de $11.45 por unidad. Tras la concesión, Mather posee directamente 2,292 valores derivados; no se divulgaron ventas ni compras adicionales de acciones comunes. Aparte de esta compensación rutinaria para directores, el informe no contiene otras transacciones materiales ni cambios en la propiedad.

Form 4 ì œì¶œì„œì— ë”°ë¥´ë©� Chemours Company(CC) ì´ì‚¬ Courtney Matherê°€ 2025ë…� 6ì›� 30ì¼ì— 2,292ê°œì˜ ì´ì—° ì£¼ì‹ ë‹¨ìœ„(DSU)ë¥� 수여받았습니ë‹�. ê°� DSUëŠ� 보통ì£� í•� ì£¼ì— í•´ë‹¹í•˜ë©°, ì´ì‚¬ê°€ ì´ì‚¬íšŒì—ì„� 물러ë‚� í›� ì²� ë‹¬ì— ì •ì‚°ë©ë‹ˆë‹�. 수여ëŠ� 단위ë‹� $11.45ì� 기준 가격으ë¡� 기ë¡ë˜ì—ˆìŠµë‹ˆë‹�. 수여 í›� MatherëŠ� ì§ì ‘ 2,292ê°œì˜ íŒŒìƒ ì¦ê¶Œì� 보유하고 있으ë©�, 보통ì£� 매ë„ë‚� 추가 매수ëŠ� 공개ë˜ì§€ 않았습니ë‹�. ì� ì¼ìƒì ì¸ ì´ì‚¬ ë³´ìƒ ì™¸ì—ëŠ� ì œì¶œì„œì— ë‹¤ë¥¸ 중요í•� 거래ë‚� 소유ê¶� ë³€ë™ì´ 없습니다.

Le formulaire Form 4 indique que la directrice de Chemours Company (CC), Courtney Mather, a reçu 2 292 unités d'actions différées (DSU) le 30 juin 2025. Chaque DSU équivaut à une action ordinaire et sera réglée dans le premier mois suivant le départ de la directrice du conseil d'administration. L'attribution est enregistrée à un prix de référence de 11,45 $ par unité. Après l'attribution, Mather détient directement 2 292 titres dérivés ; aucune vente ni achat supplémentaire d'actions ordinaires n'a été divulgué. En dehors de cette attribution de rémunération habituelle pour les administrateurs, le dépôt ne contient aucune autre transaction importante ni changement de propriété.

Das Formular Form 4 berichtet, dass die Direktorin von Chemours Company (CC), Courtney Mather, am 30. Juni 2025 mit 2.292 aufgeschobenen Aktienanteilen (DSUs) ausgezeichnet wurde. Jede DSU entspricht einer Stammaktie und wird im ersten Monat nach dem Ausscheiden der Direktorin aus dem Vorstand abgewickelt. Die Zuteilung wurde zu einem Referenzpreis von 11,45 $ pro Einheit erfasst. Nach der Zuteilung besitzt Mather direkt 2.292 derivative Wertpapiere; Verkäufe oder zusätzliche Käufe von Stammaktien wurden nicht offengelegt. Abgesehen von dieser routinemäßigen Vergütung für Direktoren enthält die Meldung keine weiteren wesentlichen Transaktionen oder Eigentumsänderungen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Groen Eric

(Last) (First) (Middle)
C/O GENELUX CORPORATION
2625 TOWNSGATE ROAD, SUITE 230

(Street)
WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GENELUX Corp [ GNLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel & Secretary
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $2.83 07/01/2025 A 270,000 (1) 06/30/2035 Common Stock 270,000 $0 270,000 D
Explanation of Responses:
1. 25% of the shares shall vest on July 1, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.
/s/ Eric Groen 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Chemours (CC) director Courtney Mather receive on 30 June 2025?

He was granted 2,292 deferred stock units, each equal to one share of common stock.

When will Courtney Mather’s deferred stock units be paid out?

The DSUs become payable in the first month following his termination of service as a director.

What reference price was used for the DSU award?

The filing lists a price of $11.45 per unit.

Did the Form 4 disclose any sales of Chemours stock by the director?

No. The report shows no disposals; only the DSU grant was recorded.

How many Chemours derivative securities does Courtney Mather own after the transaction?

He directly owns 2,292 deferred stock units following the grant.

Is Courtney Mather an officer or a director of Chemours?

The filing designates him as a Director; he is not listed as an officer.
Genelux Corp

NASDAQ:GNLX

GNLX Rankings

GNLX Latest News

GNLX Latest SEC Filings

GNLX Stock Data

133.30M
33.45M
11.41%
20.06%
6.13%
Biotechnology
Pharmaceutical Preparations
United States
WESTLAKE VILLAGE